NRXSHealthcare · BiotechnologyThe 2 Wall Street analysts covering NeurAxis, Inc. hold a median 12-month price target of $11 — +45.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores NeurAxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NRXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +45.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 22 Dec 2025 | Craig-Hallum | Maintains | Buy | — |
| 16 June 2025 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NRXS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, NeurAxis, Inc. returned +150.0% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 9% of US stocks
Cheaper than 7% of US stocks
Cheaper than 86% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 94% of US stocks
Higher than 13% of US stocks
Higher than 4% of US stocks
Higher than 10% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeurAxis, Inc. has a market value of $92.4M and an enterprise value of $84.4M.
Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 115.7% year on year.
Net income over the same four quarters: −$7.7M, a −144.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.7M.
Trailing P/E: −7.8×; forward P/E: −27.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
NeurAxis, Inc. employs 24 people — $222K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeurAxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeurAxis said it will report summarized financial results for the third quarter ended September 30, 2026, before market open on Monday, November 9, 2026.
Why it matters — NRXS watchers may follow the scheduled results and business update for information about the company’s third-quarter performance.
NeurAxis announced a medical policy coverage milestone, adding 26 million covered lives and bringing PENFS’s total national coverage footprint to over 147 million.
Why it matters — The expanded coverage footprint is relevant to NRXS watchers because it reflects broader coverage for the company’s PENFS therapy.
NeurAxis, Inc. announced the appointment of Craig Blanchard as Chief Commercial Officer on September 29, 2026. The company, which commercializes neuromodulation therapies for chronic conditions in children and adults, said the appointment positions it for the next phase of commercial growth.
Why it matters — A new Chief Commercial Officer signals NeurAxis's focus on advancing its commercial strategy and growth phase, which is relevant for investors tracking the company's development.
NeurAxis announced a medical coverage policy milestone, with a major national health insurer adding coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), expanding access to over 18 million additional covered lives.
Why it matters — Expanded insurance coverage could broaden patient access to NeurAxis's PENFS therapy, potentially supporting wider adoption of its neuromodulation treatments.
NeurAxis, Inc. announced it will participate in the Lytham Partners Fall 2026 Investor Conference, delivering a webcast presentation and hosting one-on-one investor meetings virtually on September 29-30, 2026.
Why it matters — The company's investor-conference participation increases its visibility and provides an opportunity to communicate its neuromodulation therapies to the investment community.
The 2 Wall Street analysts covering NeurAxis, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering NeurAxis, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeurAxis, Inc. 67 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, NeurAxis, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +45.7% from the last close, and Ticker Nerd's factor model ranks NeurAxis, Inc. 67 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeurAxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.
NeurAxis, Inc. returned +150.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026". NeurAxis said it will report summarized financial results for the third quarter ended September 30, 2026, before market open on Monday, November 9, 2026.
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. The company serves pediatric and adult patients through healthcare settings such as hospitals and clinics, where its therapies are used to support symptom management in targeted gastrointestinal conditions. NeurAxis also works to commercialize evidence-based devices that address unmet needs in digestive health and related neuromodulation care. Headquartered in Carmel, Indiana, NeurAxis operates as a specialized player in the medical device market with a focus on non-invasive treatment options.
CEO Mr. Brian Carrico · 24 employees · United States · https://neuraxis.com
